Full history for every metric is available with a Kvantra account
Kangji Medical Holdings Limited (9997.HK)
Key financial summary
Financials in CNY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 503 | 511 | 690 | 786 | 926 | 1,009 | 1,047 |
| Operating profit | CNY m | 593 | 591 | |||||
| Net profit | CNY m | 206 | 250 | 457 | 479 | 504 | 581 | 561 |
| EPS reported | CNY | 0.49 | 0.48 | |||||
| Operating cashflow per share | CNY | 0.48 | 0.48 | |||||
| Capex per share | CNY | 0.05 | 0.05 | |||||
| FCF per share | CNY | 0.43 | 0.43 | |||||
| Free cash flow | CNY m | 505 | 485 | |||||
| Net debt | CNY m | -1,243 | -1,771 | |||||
| Book value equity | CNY m | 2,629 | 2,594 | |||||
| Book value per share | CNY | 2.24 | 2.20 | |||||
| Number of shares | m | 1,175.75 | 1,178.07 | |||||
| DPS (TTM paid) | CNY | 0.24 | 0.22 |
Financial summary
Financials in CNY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 12.02 | - | |||||
| P/B LTM | x | 2.63 | 3.57 | |||||
| P/S LTM | x | 6.86 | 8.85 | |||||
| P/FCF LTM | x | 13.72 | 19.09 | |||||
| EV/EBITDA LTM | x | 10.31 | 12.13 | |||||
| EV/Sales LTM | x | 5.75 | 7.16 | |||||
| Earnings Yield LTM | % | 8.32% | 6.29% | |||||
| FCF Yield | % | 7.29% | 5.24% | |||||
| Quality | ||||||||
| ROE | % | 22.12% | 18.52% | |||||
| ROIC | % | 18.58% | 18.58% | |||||
| Operating margin | % | 58.76% | 58.76% | |||||
| Gross margin | % | 79.08% | 79.08% | |||||
| FCF/Sales | % | 50.02% | 50.02% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +13.95% | +6.67% | |||||
| Sales Growth YoY | % | +8.92% | +6.72% | |||||
| Net Income Growth YoY | % | +15.36% | +5.04% | |||||
| FCF Growth | % | +52.10% | +30.04% | |||||
| Operating Profit Growth | % | +33.95% | +20.39% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 23.79% | 2.84% | |||||
| Dividend Growth | % | -83.20% | - | |||||
| Payout Ratio | % | 283.32% | 2.83% | |||||
| FCF/Debt | x | 143.53 | 527.05 | |||||
| Net Debt/EBITDA | x | -2.00 | -2.00 | |||||
| EBIT/Net interest | x | 931.90 | 931.90 | |||||
| Net debt/market cap | % | -17.95% | -19.11% | |||||
| Net debt/Equity | x | -0.47 | -0.68 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Kangji Medical Holdings Limited, together with its subsidiary companies, focuses on the entire lifecycle of advanced minimally invasive surgical instruments and their accessories, from initial design and development to manufacturing and sales, primarily serving the Chinese market. The company's extensive product range includes various single-use instruments, such as trocars, polymer ligation clips, electrocoagulation forceps, and ultrasonic scalpels, alongside other disposable hand-held devices. Complementing these are its multi-use offerings, which feature reusable trocars and forceps, among other re-sterilizable products. These specialized tools are utilized across several medical disciplines, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. Kangji Medical primarily distributes its products through an established network of distributors. The company, which has its headquarters in Hangzhou, China, commenced operations in 2004.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kangji Medical Holdings Limited (9997.HK)
Kangji Medical Holdings Limited, together with its subsidiary companies, focuses on the entire lifecycle of advanced minimally invasive surgical instruments and their accessories, from initial design and development to manufacturing and sales, primarily serving the Chinese market. The company's extensive product range includes various single-use instruments, such as trocars, polymer ligation clips, electrocoagulation forceps, and ultrasonic scalpels, alongside other disposable hand-held devices. Complementing these are its multi-use offerings, which feature reusable trocars and forceps, among other re-sterilizable products. These specialized tools are utilized across several medical disciplines, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. Kangji Medical primarily distributes its products through an established network of distributors. The company, which has its headquarters in Hangzhou, China, commenced operations in 2004.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free